Armata Pharmaceuticals, Inc. (ARMP) Form 8-K — May 13, 2026
On May 13, 2026, Armata Pharmaceuticals, Inc. entered into a secured term loan facility with Innoviva Strategic Opportunities LLC, a wholly owned subsidiary of Innoviva, Inc., a principal shareholder of the company. The loan facility is for an aggregate amount of $25 million, with an interest rate of 14.0% per annum and a maturity date of January 11, 2029. The loan is guaranteed by the company's domestic subsidiaries and secured by substantially all of the company's assets.
Key figures
- Debt Amount
- 25000000
- Interest Rate
- 14
- Maturity Date
- 2029-01-11
Price after filing
Close on the filing date to close N calendar days later (from $8.82). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.